<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04575701</url>
  </required_header>
  <id_info>
    <org_study_id>1465/2018</org_study_id>
    <nct_id>NCT04575701</nct_id>
  </id_info>
  <brief_title>Long-term Outcome of TNF Alpha Therapy in IBD</brief_title>
  <official_title>Long-term Outcome of TNF Alpha Therapy in IBD</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Medical University of Graz</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Medical University of Graz</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of this retrospective study is to assess the outcome of patients with inflammatory&#xD;
      bowel disease (IBD) under TNF-alpha antibody therapy over a period of 20 years&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Long-term results published so far show that over the years a large part of patients have to&#xD;
      stop TNF Alpha antibody therapy in IBD. Reasons are mostly loss of effectiveness or&#xD;
      intolerance or side effects. Reasons for the termination are usually poorly characterized&#xD;
      with regard to the exact reason and time. As a consequence, the aim of this retrospective&#xD;
      study is to assess the outcome of patients with inflammatory bowel disease under TNF-alpha&#xD;
      antibody therapy over a period of 20 years&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">May 1, 2019</start_date>
  <completion_date type="Actual">July 1, 2020</completion_date>
  <primary_completion_date type="Actual">June 1, 2020</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Other</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Length of first TNF Alpha Therapy in IBD patients</measure>
    <time_frame>20 years</time_frame>
    <description>The main endpoint of this retrospective Analysis is the length of Treatment with the first TNF Alpha therapy in IBD</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Rate of further biologicals after first TNF Alpha therapy</measure>
    <time_frame>20 years</time_frame>
    <description>Follow-up drug therapy after termination of TNF Alpha therapy</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of surgical interventions after first TNF Alpha</measure>
    <time_frame>20 years</time_frame>
    <description>Resections after the termination of first TNF Alpha therapy</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Reasons for discontinuing therapy</measure>
    <time_frame>20 years</time_frame>
    <description>Loss of response, side effects etc.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Predictive factors</measure>
    <time_frame>20 years</time_frame>
    <description>Predictive factors for long-term response (BMI, CRP, Alb etc.)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of side effects</measure>
    <time_frame>20 years</time_frame>
    <description>Side effects of the primarily used TNF-alpha antibodies leading to discontinuation of the drug</description>
  </secondary_outcome>
  <number_of_groups>3</number_of_groups>
  <enrollment type="Actual">538</enrollment>
  <condition>IBD</condition>
  <arm_group>
    <arm_group_label>Ulcerative Colitis (UC)</arm_group_label>
    <description>This Group includes all patients suffering from UC who have been treated with a TNF Alpha antibody within the last 20 years at the IBD outpatient clinic at our Hospital.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Crohn's disease (CD)</arm_group_label>
    <description>This Group includes all patients suffering from CD who have been treated with a TNF Alpha antibody within the last 20 years at the IBD outpatient clinic at our Hospital.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>IBD unclassified</arm_group_label>
    <description>This Group includes all patients suffering from IBD unclassified who have been treated with a TNF Alpha antibody within the last 20 years at the IBD outpatient clinic at our Hospital.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>TNF Alpha therapy</intervention_name>
    <description>Retrospective analysis of outcome of first TNF Alpha therapy</description>
    <arm_group_label>Crohn's disease (CD)</arm_group_label>
    <arm_group_label>IBD unclassified</arm_group_label>
    <arm_group_label>Ulcerative Colitis (UC)</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        The study Population includes all patients with a confirmed IBD diagnosis who have been&#xD;
        treated with an TNF Alpha antibody in the last 20 years at our outpatient clinic in Graz,&#xD;
        Austria&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients with a confirmed IBD diagnosis&#xD;
&#xD;
          -  TNF Alpha antibody therapy in the last 20 years at our outpatient clinic&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Not Meeting the inclusion criteria&#xD;
&#xD;
          -  Lack of clinical data, no follow up available&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Wolfgang Petritsch, Prof</last_name>
    <role>Principal Investigator</role>
    <affiliation>Meduni Graz</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Medical University of Graz</name>
      <address>
        <city>Graz</city>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Austria</country>
  </location_countries>
  <verification_date>February 2021</verification_date>
  <study_first_submitted>September 29, 2020</study_first_submitted>
  <study_first_submitted_qc>September 29, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">October 5, 2020</study_first_posted>
  <last_update_submitted>February 23, 2021</last_update_submitted>
  <last_update_submitted_qc>February 23, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">February 25, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

